$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Medical Research

FDA Approves Weekly Sogroya For Turner Syndrome Growth

The FDA has approved once-weekly Sogroya for children 2.5 and older with growth failure from Turner syndrome, after a 105-patient trial showed growth close to daily injections over 52 weeks.

TML Health DeskNov 20, 2:10 PM ET · 2 min read

Edited and fact-checked by Stephen Sprague

A Turner syndrome karyotype in an archive photo. /wikimedia
Summary

The approval swaps a daily shot for a weekly one at comparable growth, and the trial's comparator dose sits below the approved daily maximum.

Tap a passage. React to the part that matters.

A child with Turner syndrome who starts growth hormone faces an injection every day for years. The Food and Drug Administration approved Sogroya, Novo Nordisk's once-weekly growth hormone, on November 20 for children aged 2.5 years and older whose growth failure comes from Turner syndrome, and the drug is the first weekly option approved for the condition, so the daily routine is the burden it removes.

The approval rests on REAL8, a randomized phase 3 trial that enrolled 105 children with Turner syndrome aged 2.5 to 10 years, with 68 children on Sogroya at 0.24 milligrams per kilogram once a week and 37 on daily somatropin at 0.05 milligrams per kilogram each day. Annualized height velocity at week 52 was the primary endpoint, and REAL8 is a basket study, so one randomized framework tested the weekly drug across several growth conditions at once.

Children on the weekly drug grew 8.9 centimeters a year against 9.7 centimeters a year on daily somatropin, an estimated difference of minus 0.8 centimeters with a confidence interval that crosses zero. Height standard deviation scores rose 0.77 on Sogroya and 0.86 on the daily drug, and the release describes the weekly growth rate as comparable rather than superior.

The comparison carries a limit that families should see plainly, because the daily arm used 0.05 milligrams per kilogram while the approved maximum daily dose for Turner syndrome in the United States is 0.067. The trial ran open-label, so families and investigators knew which schedule each child followed, and participants are continuing in a two-year safety extension that hasn't reported yet.

Dr. Aristides Maniatis, a REAL8 investigator at Rocky Mountain Endocrinology, said daily therapy works well and staying consistent gets hard for families who manage several conditions and medicines at once. A weekly schedule gives a child 313 injection-free days a year, he said, and Colleen Silk, Novo's group vice president for rare disease, said the company built the option around how children and caregivers actually live.

Turner syndrome affects about 1 in 2,000 female newborns, and it most often causes short stature along with possible heart and kidney problems. Reactions in at least 10 percent of the Turner cohort included respiratory tract infection, nasopharyngitis, ear infection, fever, diarrhea, vomiting and injection site reactions. Sogroya now carries five approved growth indications in children, and the label lists three strengths, 5, 10 and 15 milligrams, given as one injection under the skin each week.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.